NUC

Simply NUC® Launches Cypress Long-Life Mini PC Powered by Latest AMD® Ryzen™ Embedded Processors

Thursday, October 14, 2021 - 2:00pm

AUSTIN, Texas and BELFAST, United Kingdom and DUNLEER, Ireland, Oct. 14, 2021 /PRNewswire/ --

Key Points: 
  • Cypress, an extension of Simply NUC's Long-Life Mini roadmap, features AMD Ryzen Embedded V2000-series processors, AMD RadeonGraphics, and a 7-year commitment to supply
    Simply NUC, Inc, a leading mini computer integration company, recently announced Cypress, a new Simply NUC branded Long-Life Mini PC.
  • Cypress is the first 4x4 Mini PC featuring V2000 Embedded AMD processors and will be sold in the same form, fit, and function for seven years from launch.
  • As always, Simply NUC will have your custom-built Cypress Mini PC shipped within 48 hours of receiving your order.
  • Simply NUC provides fully configured, warrantied, and supported mini PC systems to businesses and consumers, as well as end-to-end NUC project development, custom operating system installations, and NUC accessories.

Camect Powers Up AI on 4K Cameras With 11th Gen Intel® Core™ Processors

Monday, October 4, 2021 - 3:30pm

Camect, with industry leading analytics accuracy for video surveillance, has optimized its software on 11th Generation Intel Core processors to increase performance and process artificial intelligence (AI) simultaneously across more cameras.

Key Points: 
  • Camect, with industry leading analytics accuracy for video surveillance, has optimized its software on 11th Generation Intel Core processors to increase performance and process artificial intelligence (AI) simultaneously across more cameras.
  • Camect smart camera hubs with 11th Generation Intel Core processors are now able to process analytics for up to twelve 4K cameras, or 96 MP of total camera resolution.
  • Intel recently released the 11th Generation Intel Core processors with Iris Xe Graphics, representing a significant leap forward in integrated GPU performance.
  • Camect has optimized its software to efficiently process camera video and AI on the latest 11th generation Intel NUC systems built on these processors.

VSBLTY CEO PROVIDES CORPORATE UPDATE WITH Q2 BOOKINGS EXCEEDING $4 MILLION USD & 165% BILLINGS GROWTH

Tuesday, August 24, 2021 - 12:40pm

VSBLTY CEO & Co-founder Jay Hutton said, The company is pleased to report that the second quarter yielded strong billings growth at 165% over Q1.

Key Points: 
  • VSBLTY CEO & Co-founder Jay Hutton said, The company is pleased to report that the second quarter yielded strong billings growth at 165% over Q1.
  • This Q2 contract value, when compared against our Q2 billings, gives us a strong ratio of 14:1.
  • As a SaaS company we know that bookings lead with revenue billings to follow.
  • Under the License Agreement, VSBLTY will receive a payment of $2 million USD, payable based upon certain milestones being achieved.

Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-721, Its Oral Hepatitis B Virus RNA Destabilizer

Monday, August 16, 2021 - 12:00pm

We are pleased to advance our HBV program by dosing the first subject in our Phase 1 clinical study of EDP-721, an orally administered HBV RNA destabilizer that has the potential to reduce S antigen.

Key Points: 
  • We are pleased to advance our HBV program by dosing the first subject in our Phase 1 clinical study of EDP-721, an orally administered HBV RNA destabilizer that has the potential to reduce S antigen.
  • The current standard of care for chronic HBV involves nucleoside reverse transcriptase inhibitors, or NUCs, which can suppress HBV replication.
  • This two-part Phase 1a/b study will initially evaluate the safety, tolerability, and pharmacokinetics of EDP-721 in single and multiple ascending oral doses in healthy volunteers.
  • Enantas research and development efforts have produced clinical candidates for the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV), non-alcoholic steatohepatitis (NASH), and SARS-CoV-2 (COVID-19).